Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
US10167253B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10167253-B2 |
| Application number | US-201615191511-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 23, 2016 |
| Priority date | Jun 24, 2015 |
| Publication date | Jan 1, 2019 |
| Grant date | Jan 1, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.
Opening claim text (preview).
What is claimed is: 1. A compound comprising the structure shown in Formula I wherein R 1 and R 2 are R 1 =CH 2 (CH 2 ) n OC(═O)R 4 R 2 =CH 2 (CH 2 ) m OC(═O)R 5 wherein n and m are each independently from 1 to 2; and R 4 and R 5 are independently for each occurrence a C(12-20) alkyl group, or a C(12-20) alkenyl group; wherein R 3 is selected from wherein each R 6 is independently selected from H, alkyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkoxy, and aminoalkyl; each R 7 is independently selected from H, alkyl, hydroxyalkyl, and aminoalkyl; Q is O or NR 7 . 2. The compound of claim 1 , wherein alkyl is C(1-6)alkyl, hydroxyalkyl, is hydroxyl[C(1-6)alkyl], and aminoalkyl is amino[C(1-6)alkyl]. 3. The compound of claim 1 , R 4 and R 5 are independently for each occurrence a C(14-18) alkyl group, or a C(14-18) alkenyl group. 4. The compound of claim 1 , wherein Q is O. 5. The compound of claim 1 , having a structure selected from 6. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 7. The composition of claim 6 , wherein the composition comprises nanoparticles. 8. A pharmaceutical composition comprising a compound of claim 1 , an active agent, and a pharmaceutically acceptable carrier. 9. The composition of claim 8 , wherein the compound is from 15 mol % to 40 mol % of the lipids of the composition. 10. The composition of claim 8 , wherein the composition comprises nanoparticles. 11. The composition of claim 8 , wherein the active agent is one or more RNAi molecules. 12. The composition of claim 8 , wherein the active agent is one or more RNAi molecules selected from small interfering RNAs (siRNA), double stranded RNAs (dsRNA) that are Dicer substrates, microRNAs (miRNA), short hairpin RNAs (shRNA), DNA-directed RNAs (ddRNA), Piwi-interacting RNAs (piRNA), repeat associated siRNAs (rasiRNA), and modified forms thereof. 13. A composition for use in distributing an active agent for treating a condition or disease in a subject, the composition comprising a compound of claim 1 , a structural lipid, a stabilizer lipid, and a lipid for reducing immunogenicity of the composition. 14. The composition of claim 13 , wherein the active agent is one or more RNAi molecules and the composition comprises nanoparticles that encapsulate the RNAi molecules. 15. The composition of claim 14 , wherein the active agent is one or more RNAi molecules selected from small interfering RNAs (siRNA), double stranded RNAs (dsRNA) that are Dicer substrates, microRNAs (miRNA), short hairpin RNAs (shRNA), DNA-directed RNAs (ddRNA), Piwi-interacting RNAs (piRNA), repeat associated siRNAs (rasiRNA), and any modified forms thereof. 16. A method for ameliorating or treating a disease or condition in a subject in need comprising administering to the subject a composition of claim 8 .
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title
Oxygen or sulfur atoms · CPC title
without P—C bonds · CPC title
Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.